NanoCelex Development Process

Cell culture assay to test genetically modified seed

sample text for news, o nanoCelex platform covers target discovery to identification of lead antimicrobial antibody fragments. The lead protein targets from various pathogens are identified through extensive bioinformatics and biochemical analyses and used for screening our nanoCelex antibody fragment libraries in vitro. Screening of the library will be done for multiple rounds and by applying desired selective pressure at each round to ultimately develop the optimal binding variants with desired features, e.g. resistance against heat and proteases. The optimized sequence will be further engineered for expression in appropriate expression systems and produced at commercial scale for various applications. Our infrastructure, expertise and access to large collections of well-defined environmental or clinical samples, will make AbCelex an excellent partner for discovery, development and commercialization of new diagnostic assays and devices.

AbCelex Technologies Secures Two Million in Series A Financing

TORONTO, ONTARIO, April 28, 2014 | AbCelex Technologies Inc., a privately-held Canadian biotechnology company committed to the discovery and development of innovative solutions to advance the health of food animals and human food safety, announced today it has closed on $2.0 million in Series A venture capital financing. The round was led by Cultivian Sandbox Ventures, LP, a Chicago-based fund with substantial expertise in agriculture and industrial biotechnology sectors.

The funds will support research and development of the company’s antibody-based approach to control pathogens in farm animals related to food-borne illnesses. With a growing world population, human food safety remains a pressing challenge. The Centers for Disease Control and Prevention in the U.S. report that in the U.S. about 1 in 6, or 48 million, people get sick each year from contaminated food with 128,000 hospitalizations and 3,000 deaths annually. Increasing health concerns over microbial resistance to antibiotics is driving government regulators to encourage alternatives to the regular use of antibiotics in farm animals.

AbCelex Technologies is pleased to welcome Ron Meeusen, Matthew Bell, and Paul Dick to the Company’s Board of Directors.

Ron Meeusen, PhD

Dr. Meeusen is a Managing Director of Cultivian Sandbox and co-founder and Managing Partner of Cultivian Ventures. Ron has over 30 years of experience in bringing new technologies and products to market. He has led research and development for major corporations in agricultural chemicals, field crop and vegetable genetics and breeding, animal health, novel foods and industrial materials. Ron has been a frequent speaker at conferences, a consultant to Federal policy on biotechnology regulatory issues, and active in industry trade groups. Prior to forming Cultivian Ron led the expansion of the biotechnology research and development program of Dow AgroSciences, and founded a successful biopharmaceutical company, Immuneworks, Inc. Ron represents Cultivian on the board of directors of Allylix, Proterro and Rivertop Renewables, and represents Cultivian Sandbox on the board of EnEvolv. He was also a member of the boards of directors of Divergence, Inc., which was sold to Monsanto Company in February of 2011, and of Aratana Therapeutics, which went public in 2013. Ron holds a Ph.D. from the University of California, Berkeley in plant cell biology.

Matthew Bell

Mr. Bell is a Principal of Cultivian Sandbox. Matt has over 9 years of technology commercialization and startup experience through his time with the University of Michigan’s Office of Technology Transfer where he was directly involved with the formation activities of over 20 startup companies. Prior to working at the University, Matt spent over 10 years in the Agriculture industry working for several production Ag supply companies including Growmark Incorporated where he was involved with their highly regarded precision farming services group. Matt has two degrees from the University of Illinois in Agronomy and a Masters of Business Administration and spent much of his early career as a professional grain farmer on the family farm that he grew up on in Central Illinois.

Paul Dick, DVM, MSc

Dr. Dick has 25 years of experience in the animal health industry including product development, regulatory affairs, business development, commercialization and general management. Roles in this sector have involved both large and medium multinationals and small start-up companies, in various capacities including COO of Naturagen Health Solutions within Elanco and CEO of Chemaphor involved in development of pharmaceuticals and veterinary natural health products. Dr. Dick has worked extensively with Health Canada’s Veterinary Drugs Directorate and the Canadian Food Inspection Agency on numerous regulatory submissions and on departmental committees. He has served a number of organizations including as Director of the Canadian Animal Health Institute, President of the Ontario Veterinary Medical Association, and peer reviewer of NSERC strategic grants. He holds a veterinary degree with advanced training in infectious diseases and immunology.

“Backed by Cultivian Sandbox Ventures, we are well on our way to developing our lead anti-Campylobacter product for poultry. AbCelex’s antibody-based approach to controlling harmful pathogens is poised to have a dramatic impact on human food safety”, said Dr. Babaei, President & CEO of AbCelex Technologies. “Our innovative intellectual property platform combined with our proprietary genomics know-how allows us to deliver unique antimicrobial solutions against various pathogens in multiple farm animal species.”

“AbCelex has some exciting next-generation biotechnology to address some of the world’s pressing food safety challenges”, said Dr. Meeusen of Cultivian Sandbox. “The team at AbCelex has overcome the difficulties in delivering antimicrobial antibodies through oral administration to farm animals. Their feed additive approach will revolutionize the treatment of many food-borne pathogens improving food safety for all of mankind.”

About Cultivian Sandbox Ventures

Cultivian Sandbox is a venture capital firm focused on building next-generation disruptive agriculture and food technology companies capable of generating superior returns. As both experienced operating managers and venture investors we add value to portfolio companies both through our highly skilled team and extensive industry network. Our expertise in sourcing, evaluating, closing, managing and ultimately exiting successful equity investments positions us not only to build stronger businesses, but reshape industries. Additional information can be found at: http://www.cultiviansbx.com.

About AbCelex Technologies Inc.

AbCelex Technologies Inc., is a privately-held Canadian biotechnology company committed to the discovery and development of innovative solutions to advance the health of food animals and improve human food safety. Employing advanced genetics and bioengineering techniques, AbCelex’s antibody based approach delivers antimicrobial solutions against various pathogens in several food animal species implicated in food-borne illnesses. For more information, visit http://www.abcelex.com.

For further information, please contact:

Saeid Babaei
(647) 494-8787; ir@abcelex.com

AbCelex Technologies to Present at VetHealth Global 2013

TORONTO, ONTARIO June 10, 2012 | AbCelex Technologies to Present at VetHealth Global 2013
The International Animal Health and Nutrition Business Conference

– AbCelex Technologies announced today that the Company has been invited to present at the upcoming VetHealth Global 2013 conference to be held June 10-12 in Princess Edward Islands, Canada.

AbCelex has been selected for the Innovation in Animal Health and Nutrition as one of the top 10 emerging companies who are bringing exciting new technologies to the marketplace to present at this global conference.

VetHealth Global has consistently attracted a top drawer group of multinational companies and early stage businesses that come together in an informal setting to share new research and product concepts, identify investment opportunities, establish new sales channels, and discuss global animal health issues and trends. Delegates from North America, the U.K., China, Switzerland, Brazil, and Israel will participate in this year’s Conference.

Information on this event can be found on the conference website: https://www.vethealthglobal.com/emerging_companies_presentations.php

About VetHealth Global 2013

VetHealth Global is North America’s Premier International Animal Health & Nutrition Business Conference. Over 150 delegates from animal health and nutrition companies and support organizations from around the world will be in Prince Edward Island, Canada from June 10 – 12th for VetHealth Global 2013. Since 2007, VetHealth Global has received recognition for its stellar list of participating presenters, innovative emerging companies, business-to-business partnering program, and top-rated networking events. For more information, visit https://www.vethealthglobal.com.

About AbCelex Technologies Inc.

AbCelex Technologies Inc. is a privately owned Canadian biotechnology company committed to the discovery and development of innovative technologies for food safety applications. AbCelex’s current efforts are catered towards the development and commercialization of diagnostic and novel feed additive products for food animal health and food safety. For more information, visit www.abcelex.com.

Enquiries:

For further information, please contact: ir@abcelex.com

AbCelex Technologies to Participate at Two Upcoming Conferences

TORONTO, ONTARIO February 21, 2012 | AbCelex Technologies Inc. announced today that the Company will be participating at two upcoming international conferences:

  • 10th Annual BioPartnering North America, February 26-28, 2012, Vancouver Convention Centre;
  • GLOBE 2012, 12th Biennial Conference & Trade Fair on Business & the Environment, March 14–16, 2012, Vancouver Convention Centre.

About AbCelex Technologies Inc.

AbCelex Technologies Inc. is a privately owned Canadian biotechnology company committed to the discovery and development of innovative technologies for the diagnosis and treatment of variety of illnesses including cancer and infectious diseases. Our current efforts are catered towards the development and commercialization of high avidity single domain antibody (sdAb)-based diagnostic and food safety products to help patients worldwide with the best care possible. For more information, visit www.abcelex.com.

About BioPartnering North America (BPN)

BioPartnering North America 2012 (BPN) brings together senior executives from venture capital firms, major pharmaceutical companies, academic institutions and biotechnology companies of every size from mature to start-up. Now in its 10th year of partnering & dealmaking, BPN is focusing on the Pacific Rim. The strategy is to build on close ties with industry leaders in the Pacific Rim to create a unique opportunity for the U.S., Canada, and Europe to meet leading life science companies from Asia.

About Globe

Having been around since 1990, GLOBE is known as the quintessential gathering of global senior business and government representatives who meet to network and to advance the issues at the nexus of global business and sustainability agendas.

Enquiries:

For further information, please contact:
ir@abcelex.com

Research Collaboration and Commercialization Agreement with the Carton Group

TORONTO, ONTARIO February 2, 2012 | AbCelex Technologies Announces Research Collaboration and Commercialization Agreement with the Carton Group

– AbCelex Technologies Inc. is pleased to announce a strategic collaboration agreement with the Carton Group.
According to the signed agreement terms, AbCelex and Carton will jointly research and develop products effective against Campylobacter jejuni. AbCelex’s proprietary antibody-based platform technology can be a substantial solution worldwide to help prevent or significantly reduce food-borne illnesses.

“I am extremely pleased for this cooperation between AbCelex and Carton where we can contribute to the reduction of C. jejuni infections and other harmful microbes which continue to be pervasive throughout our food supply chain”, said Dr. Saeid Babaei, Chairman of the Board at AbCelex. “This collaboration will provide AbCelex with an opportunity to strengthen its presence in the food safety market in partnership with one of the world’s largest food companies in the rapidly growing and profitable segment”.

“I am very excited about the opportunity to join AbCelex research team in investigating innovative technologies to reduce Campylobacter infection in our food supply as consumers, now more than ever, are vigilant when it comes to food safety,” said Mr. Vincent Carton, Managing Director at Carton Group. “Adding innovative and effective products to our portfolio is an important aspect of our business strategy in ensuring that our birds are raised to the highest food safety and animal care standards. We are firmly behind the wheel in the drive for innovation and growth in our industry.”

According to the Centers for Disease Control and Prevention (CDC), Campylobacter, primarily C. jejuni, is the third leading cause of death from foodborne infections in the world. In the United States alone, it affects nearly 2.4 million people, causes an estimated 58,000 illnesses and 200 deaths, and costs companies millions of dollars in recall losses in the U.S. each year. A substantial portion of the illnesses and deaths are associated with meat and poultry products.

A recent survey of Canadians conducted by BrandTrust found that food safety now ranks virtually equal to freshness when considering purchasing processed meats – 94% of respondents ranked food freshness as the most influential factor, with 92% also ranking food safety.

About AbCelex Technologies Inc.

AbCelex Technologies Inc. is a privately owned Canadian biotechnology company committed to the discovery and development of innovative technologies for the diagnosis and treatment of variety of illnesses including cancer and infectious diseases. Our current efforts are catered towards the development and commercialization of high avidity single domain antibody (sdAb)-based diagnostic and food safety products to help patients worldwide with the best care possible. The Company is looking at opportunities in the diagnostic market in addition to developing products for the animal health market that could help to prevent food borne infection at the animal source. For more information, visit www.abcelex.com.

About Carton Group

Carton Group with its Manor Farm brand is one of the oldest family companies in Ireland dating back to 1775 and now in its 8th generation. Today, Carton is Ireland’s largest integrated chicken processor, based in Shercock, Co Cavan, where it processes 800,000 birds per week and produces 130,000 tonnes of chicken feed a year. Carton employs over 650 people throughout the year and 750 during the summer months. In addition to this the company has 150 breeder, broiler and free-range farmers and gives indirect employment to many more throughout the 26 counties. The company recorded a turnover of €205 million in 2011 and the payroll costs came to €22 million.

About Campylobacter

Campylobacter is the cause of enteric infections that can be severe enough to cause death or serious neurological damage. It is a major public health issue with a considerable socio-economic impact. Foods are a significant risk factor for human campylobacteriosis, and the infectious dose seems to be very low. Poultry-based foods are assumed to be the primary source of campylobacteriosis, with the main routes of infection being the ingestion of inadequately cooked meat (primarily poultry) and cross-contamination.

Enquiries:

For further information, please contact:
Dr. Saeid Babaei
ir@abcelex.com

AbCelex Technologies and National Research Council of Canada Sign Strategic Partnership Agreement

TORONTO, ONTARIO April 20, 2011 | AbCelex Technologies Inc. today announced that it has entered into an exclusive worldwide licensing and collaboration agreement with the National Research Council Institute for Biological Sciences (NRC-IBS) to access their Pentabody platform technology.

Under the agreement, AbCelex has an exclusive worldwide license to develop and commercialize NRC-IBS’s Pentabody platform for all in vitro clinical diagnostic applications. NRC-IBS will receive an up-front payment and milestone payments in addition to royalties on future product sales.

About AbCelex Technologies Inc.

AbCelex Technologies Inc. is a privately owned Canadian biotechnology company focused on creating innovative new products for rapid diagnosis of a diverse set of disease-associated biomolecules. Our efforts are catered towards the development and commercialization of signature-based diagnostic products with a high clinical value that help to provide patients worldwide with the best individual care possible. For more information, visit www.abcelex.com.

About NRC-IBS

Recognized globally for research and innovation, the NRC is a leader in the development of an innovative, knowledge-based economy for Canada through science and technology. The NRC operates world-class research facilities, as well as information, technology and innovation support networks from coast to coast. Its outstanding people help turn ideas and knowledge into new products, processes and services, creating value for Canada. The NRC works hand in hand with partners from industry, government and universities to help ignite the spark of innovation in communities across the land and to give Canadian companies a competitive edge in today’s marketplace (www.nrc-cnrc.gc.ca).

Enquiries:

For further information, please contact: Saeid Babaei (647) 494-8787 ir@abcelex.com

News